|
Targeting B-cell lymphoma with Leukothera-phase II
|
5R42CA173900-03
|
$894,222
|
$894,222
|
BELINKA, BENJAMIN
|
ACTINOBAC BIOMED, INC.
|
|
Automated Ultrasensitive Detection of Light Chain Restriction in Lymphoproliferat
|
5R44CA168019-03
|
$529,530
|
$529,530
|
MA, XIAO-JUN
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Ant
|
1R44CA195812-01A1
|
$961,768
|
$961,768
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
5R42CA183708-04
|
$499,411
|
$499,411
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
$611,800
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Lig4R278H contribution to HSC and IgH class switching defects and malignancies
|
5R01CA161151-03
|
$365,484
|
$182,742
|
YAN, CATHERINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
$16,737
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$1,709
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$40,518
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$498,373
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-05
|
$738,521
|
$738,521
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein in B Cell Growth Transformation
|
5R01CA047006-28
|
$565,231
|
$282,616
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
5R01CA085180-14
|
$701,405
|
$350,703
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
5R01CA170023-03
|
$392,517
|
$196,259
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
$741
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
$1,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-25
|
$4,878,887
|
$97,578
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
$8,590
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
$68,012
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL
|
1R43CA192540-01
|
$299,052
|
$299,052
|
GUYRE, PAUL
|
CELDARA MEDICAL, LLC
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S1
|
|
$0
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S2
|
$64,741
|
$5,179
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S3
|
$229,232
|
$18,339
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S4
|
$593,811
|
$47,505
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S5
|
$917,771
|
$73,422
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S6
|
$68,356
|
$5,468
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S7
|
$778,576
|
$62,286
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S8
|
$73,651
|
$5,892
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-02
|
$24,080,302
|
$1,926,424
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
|
5R21CA183445-02
|
$255,780
|
$255,780
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exploring the oncogenic potential of human APOBEC3 cytosine deaminases
|
1R21CA185799-01A1
|
$182,700
|
$60,291
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
1R01CA196703-01
|
$404,316
|
$404,316
|
CHIARLE, ROBERTO
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Nonadherence: Undermining health outcomes in pediatric HSCT?
|
5R01CA157460-04
|
$267,778
|
$133,889
|
PAI, AHNA
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-10
|
$2,185,000
|
$1,398,400
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S1
|
$113,085
|
$6,785
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S2
|
$53,400
|
$3,204
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S3
|
$50,000
|
$3,000
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S4
|
$124,999
|
$7,500
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-32
|
$2,184,600
|
$131,076
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
|
5R01CA166219-04
|
$579,375
|
$579,375
|
WANG, SOPHIA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Autoimmune Conditions, Genetic Variations, and Lymphoma Etiology
|
5R03CA179558-02
|
$84,000
|
$84,000
|
WANG, SOPHIA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-02
|
$496,292
|
$496,292
|
ZAIA, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
|
1R01CA187415-01A1
|
$445,986
|
$445,986
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
5P01CA013106-44
|
$4,421,268
|
$132,638
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-28
|
$4,418,824
|
$44,188
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Identification of Loci Modifying Atm Lymphomagenesis
|
1R01CA197801-01
|
$351,973
|
$175,987
|
WEIL, MICHAEL
|
COLORADO STATE UNIVERSITY
|
|
Roles and regulation of p53
|
5P01CA087497-15
|
$1,767,603
|
$583,309
|
PRIVES, CAROL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Enhancing the vaccinal effect of antitumor antibodies
|
5R01CA164309-04
|
$332,000
|
$166,000
|
CHRISTIANO, ANGELA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Non-catalytic functions of DNA-PK in DNA repair and tumorigenesis
|
5F31CA183504-02
|
$43,120
|
$43,120
|
CROWE, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis
|
5R01CA164152-04
|
$332,000
|
$332,000
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $122,363,118
|